QIAGEN Names Jonathan M. Pratt as Chief Executive Officer, Bringing Extensive Life Sciences Leadership Experience
QIAGEN N.V. , a global provider of molecular testing and sample technologies, has announced the appointment of Jonathan M. Pratt as its new Chief Executive Officer, effective September 1, 2026. The leadership transition marks an important step for the company as it continues to focus on profitable growth, operational efficiency, innovation and long-term value creation across the life sciences and molecular diagnostics markets.
Pratt brings more than 25 years of international leadership experience spanning life sciences, laboratory technologies, healthcare, analytical instruments, software, consumables, services and bioprocessing applications. His background includes leadership of large global businesses and responsibility for commercial strategy, operations, portfolio development and organizational performance.
The appointment follows a comprehensive search conducted by QIAGEN’s Supervisory Board. According to the company, Pratt was selected because of his broad industry knowledge, international management experience and demonstrated ability to strengthen performance across global businesses.
He will take over as CEO at a time when QIAGEN is seeking to build on its established position in molecular diagnostics and life sciences while identifying opportunities to improve execution and enhance shareholder value.
Jonathan Pratt Brings Extensive Life Sciences Experience
Pratt joins QIAGEN following a long career in the life sciences and laboratory technology sectors. Most recently, he served as President and CEO of Filtration Group, where he led the company through the completion of its sale to Parker-Hannifin Corporation in August 2026.
Before joining Filtration Group, Pratt held several senior executive positions at major companies serving the laboratory and life sciences industries.
He previously served as Senior Vice President of the Waters Division at Waters Corporation. He also held the position of President of Beckman Coulter Life Sciences, a Danaher operating company, and held senior leadership roles at Pall Corporation.
These positions have given Pratt experience across multiple areas of the scientific and healthcare technology ecosystem. His professional background includes analytical instrumentation, laboratory solutions, software, consumables, services and bioprocessing technologies.
That experience is particularly relevant to QIAGEN because the company operates across several of these markets and serves customers through laboratory workflows that require integrated technologies, high-quality consumables and reliable diagnostic and research solutions.
Throughout his career, Pratt has worked with international organizations and global customer bases. His experience includes commercial execution, portfolio management, operational improvement and organizational development, all of which are expected to be important as QIAGEN continues to pursue its growth strategy.
Supervisory Board Expresses Confidence in New CEO
Stephen H. Rusckowski, Chairman of the Supervisory Board of QIAGEN, said the board unanimously determined that Pratt was the right leader for the company’s next phase.
According to Rusckowski, Pratt combines knowledge of the markets in which QIAGEN operates with a strong international track record of improving commercial execution and operational performance.
The Supervisory Board believes his experience in life sciences and laboratory technologies is closely aligned with QIAGEN’s portfolio and customer base. The company expects Pratt to build on QIAGEN’s existing foundation while advancing its objective of achieving solid and profitable growth.
The appointment also reflects QIAGEN’s broader emphasis on operational performance. As healthcare and life sciences markets continue to evolve, companies operating in molecular diagnostics and laboratory technology face growing pressure to innovate while maintaining efficiency and managing costs.
QIAGEN’s leadership transition therefore comes at an important point for the company as it balances investment in innovation with its objective of improving profitability.
Pratt Plans to Listen to Employees and Customers
In comments following his appointment, Pratt described QIAGEN as an established and trusted life sciences brand with a reputation for scientific rigor, quality and technologies supporting critical laboratory workflows around the world.
He said that the combination of QIAGEN’s talented workforce, differentiated portfolio and customer relationships was a major factor in his decision to join the company.
Rather than immediately outlining major strategic changes, Pratt said his initial priority would be to listen to QIAGEN employees and customers, understand the business in greater depth and identify opportunities to sharpen strategic choices and strengthen execution.
This approach suggests that the new CEO intends to begin his tenure with a detailed assessment of the company’s existing operations and market position.
Pratt is expected to work with QIAGEN’s leadership team to evaluate where the company can create greater impact and improve its ability to deliver on its long-term vision.
His stated objective is to work with employees across the organization to advance QIAGEN’s mission of making improvements in life possible.
Leadership Transition From Thierry Bernard
Pratt’s appointment follows the decision by Thierry Bernard to step down as CEO and Managing Director.
Bernard will remain involved during the transition period and is expected to support an orderly handover through the end of 2026. This transition arrangement is designed to help maintain continuity while Pratt assumes responsibility for the company’s operations and strategic direction.
Bernard’s departure represents a leadership change for QIAGEN after his tenure at the company. The Supervisory Board specifically acknowledged his contributions and leadership and thanked him for supporting continuity during the transition.
Maintaining operational stability during a CEO change can be particularly important for global healthcare and life sciences companies, where product development, regulatory activities, commercial relationships and research partnerships can span multiple years.
The transition period through the end of the year should provide Pratt with an opportunity to work alongside the existing leadership structure while developing a deeper understanding of QIAGEN’s business.
QIAGEN Reaffirms 2026 Financial Outlook
Despite the leadership transition, QIAGEN has reaffirmed its existing outlook for the third quarter and full year of 2026.
The company remains focused on achieving solid profitable growth by advancing its key growth pillars, improving operating efficiency and allocating capital toward opportunities that are expected to generate attractive returns.
The reaffirmation of the outlook provides an indication that the CEO transition is not expected to alter the company’s previously communicated near-term financial expectations.
QIAGEN’s focus on profitable growth reflects the importance of balancing expansion with disciplined cost management. The company operates in markets where continued technological innovation requires investment, while customers increasingly seek solutions that can deliver measurable clinical, research and operational value.
Improving operating efficiency is therefore expected to remain an important component of QIAGEN’s strategy under Pratt’s leadership.
Strategic Review Continues
In addition to its focus on operational execution, QIAGEN’s Supervisory Board continues to evaluate strategic opportunities.
The company said that the board is conducting this review with the assistance of independent financial and legal advisors. The process is intended to evaluate opportunities to create value for shareholders and other stakeholders in comparison with QIAGEN’s standalone business plan and longer-term strategic objectives.
The strategic review adds another dimension to Pratt’s incoming leadership role.
While no specific outcome has been announced, the continued evaluation of strategic opportunities indicates that QIAGEN is considering how best to position the company for sustainable long-term growth.
For the new CEO, understanding the findings of this strategic review and determining how they align with QIAGEN’s operational and commercial priorities will likely be an important part of the broader leadership transition.
Importance of QIAGEN’s Molecular Diagnostics and Life Sciences Portfolio
QIAGEN operates at the intersection of molecular diagnostics, life sciences research and laboratory technologies. Its products and solutions support laboratories, researchers, healthcare professionals and other customers in areas involving sample preparation, molecular testing and related workflows.
The company’s technologies are used across research and clinical environments, creating exposure to several important trends in healthcare and biotechnology.
These include the growing role of molecular diagnostics, advances in genomics and the increasing use of laboratory technologies to support personalized medicine and disease management.
The life sciences sector is also experiencing rapid technological change. Advances in molecular biology, sequencing, automation and data analysis are creating new opportunities for laboratory technology companies while increasing competition.
QIAGEN’s established customer relationships and global presence provide a foundation for continued growth, but maintaining that position requires ongoing innovation and effective commercial execution.
Pratt’s experience across laboratory technologies and life sciences could therefore be particularly relevant as QIAGEN evaluates its next phase of development.
Focus on Commercial Execution and Operational Performance
One of the key themes surrounding Pratt’s appointment is his experience in improving commercial and operational performance.
Global life sciences businesses often operate across complex markets with different customer requirements, regulatory environments and healthcare systems. Managing these operations requires a combination of scientific understanding, commercial discipline and strong organizational leadership.
QIAGEN said Pratt’s experience includes portfolio management, commercial execution and organizational development.
These capabilities could help the company identify opportunities to strengthen product portfolios, improve customer engagement and make more effective use of resources.
Pratt’s emphasis on listening to employees and customers also suggests a focus on understanding how QIAGEN’s technologies are being used and where the company can improve the value it provides.
Such insights could help guide decisions about product development, commercial investment and operational priorities.
New Leadership Comes at a Strategic Moment
The appointment of a new CEO provides QIAGEN with an opportunity to assess its priorities while continuing to execute its existing strategy.
The company has reaffirmed its 2026 outlook, meaning that near-term business objectives remain unchanged. At the same time, the ongoing strategic review gives management and the Supervisory Board an opportunity to evaluate longer-term options.
Pratt will inherit a business with an established global presence, a recognized brand and a portfolio spanning important areas of life sciences and molecular diagnostics.
His challenge will be to build on those strengths while identifying areas where the company can improve growth, profitability and operational performance.
His extensive international experience could also support QIAGEN’s efforts to manage a diverse global business and respond to changing market conditions.
Jonathan M. Pratt will officially assume the role of CEO on September 1, 2026, beginning a new chapter in QIAGEN’s leadership.
His more than two decades of experience across life sciences, laboratory technologies and healthcare provide a strong foundation for the role. His previous executive positions at Filtration Group, Waters Corporation, Beckman Coulter Life Sciences and Pall Corporation have given him experience across businesses and technologies closely connected to QIAGEN’s markets.
Pratt will initially focus on understanding QIAGEN’s teams, customers and operations before determining where strategic and operational improvements can have the greatest impact.
Meanwhile, Thierry Bernard will support the transition through the end of the year, helping maintain continuity as the new CEO becomes familiar with the organization.
QIAGEN has also reaffirmed its third-quarter and full-year 2026 outlook, while continuing to focus on its growth pillars, operational efficiency and disciplined capital allocation.
The company’s strategic review remains underway, with independent financial and legal advisors supporting the Supervisory Board in evaluating opportunities to create value relative to QIAGEN’s standalone business plan and long-term objectives.
With the leadership transition now set to take effect, Pratt’s first months at QIAGEN will likely be closely watched by employees, customers, investors and the broader life sciences industry. His combination of international leadership experience, laboratory technology expertise and operational focus is expected to play a central role as QIAGEN works to strengthen execution and pursue its next phase of profitable growth.
Source link: https://www.businesswire.com/
